Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
let-7c mimic is a microRNA (miRNA) therapeutic designed to restore the levels of let-7c, a member of the let-7 tumor suppressor family that is frequently downregulated in various cancers, including multiple myeloma. In multiple myeloma, the downregulation of let-7c is often mediated by DNA methylation in its promoter region. The mimic functions by negatively regulating the expression of High Mobility Group AT-Hook 2 (HMGA2), a known oncogene that promotes cell proliferation, invasion, and epithelial-mesenchymal transition (EMT). Preclinical studies have demonstrated that administration of let-7c mimics can inhibit the growth of transplanted tumors and modulate the expression of EMT-related proteins such as E-cadherin and N-cadherin, suggesting its potential as a targeted therapy for hematological malignancies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on let-7c mimic.